phrykt

Context Therapeutics Inc. (CNTX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of CNTX were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Context Therapeutics

From the latest filings

Overall: about as much buying as selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CNTX

80 funds and institutions reported CNTX shares worth $34.9M at the end of Q2 2026, about 69% of the company. The largest holder is Nextech Invest Ltd. with 8.1%.

Funds and institutions (13F) 69%Everyone else 31%

10 largest owners, by share of the company

Nextech Invest Ltd.8.1%
Deep Track Capital, LP8.1%
Soleus Capital Management, L.P.7.7%
BlackRock, Inc.6.7%
Avidity Partners Management LP5.4%
Franklin Resources Inc4.1%
Vanguard Capital Management LLC3.7%
Octagon Capital Advisors LP3.3%
Blue Owl Capital Holdings LP3.2%
TCG Crossover Management, LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nextech Invest Ltd.7.42M8.08%$4.1MNo change
Deep Track Capital, LP7.42M8.08%$4.1MNo change
Soleus Capital Management, L.P.7.06M7.69%$3.9M+1%
BlackRock, Inc.6.17M6.71%$3.4M+629%
Avidity Partners Management LP5.00M5.44%$2.8M-50%
Franklin Resources Inc3.80M4.14%$2.1MNo change
Vanguard Capital Management LLC3.43M3.74%$1.9MNo change
Octagon Capital Advisors LP3.05M3.32%$1.7M-42%
Blue Owl Capital Holdings LP2.93M3.19%$1.6M-42%
TCG Crossover Management, LLC2.68M2.92%$1.5MNo change
Geode Capital Management, LLC1.83M1.99%$1M+203%
State Street Corp1.41M1.54%$783K+505%
Mpm Bioimpact LLC1.30M1.41%$720K-88%
Renaissance Technologies LLC1.04M1.13%$577K+469%
Acadian Asset Management LLC1.01M1.10%$559KNew
ADAR1 Capital Management, LLC750,9690.82%$416K+114%
Jane Street Group, LLC645,2090.70%$357K+48%
Vanguard Portfolio Management LLC638,8780.70%$354KNew
Northern Trust Corp615,5760.67%$341K+496%
Vanguard Fiduciary Trust Co433,8880.47%$240K+27%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No CNTX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CNTX short interest

Moderate short interest. 5.1% of CNTX shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went up 410%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.70M CNTX shares were sold short, 5.1% of the shares outstanding, up 9.9% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 3.7 trading days (days to cover).

Shares short, % of all shares

5.11%May 15Oct 308.51%

Days to cover

3.7May 15Oct 306.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.70M5.11%+10%1.28M3.7
Oct 15, 20264.27M4.65%-9%841,2385.1
Sep 30, 20264.71M5.12%-32%1.17M4.0
Sep 15, 20266.91M7.52%+7%1.21M5.7
Aug 31, 20266.47M7.04%+3%2.58M2.5
Aug 14, 20266.27M6.83%+8%2.00M3.1
Jul 31, 20265.83M6.35%-12%1.38M4.2
Jul 15, 20266.63M7.22%+106%3.66M1.8
Jun 30, 20263.21M3.49%+276%4.94M1.0
Jun 15, 2026854,6720.93%-5%2.43M1.0
May 29, 2026896,0560.98%-3%826,6121.1
May 15, 2026920,2111.00%+2%514,9231.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Context Therapeutics company events

Context Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementThe Company updated its corporate presentation. Filing
  2. Aug 5, 2026AnnouncementShared information with investors. Filing
  3. Jul 31, 2026ListingContext Therapeutics Inc. received written notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock failed to maintain a minimum closing bid price of… Filing
  4. Jun 26, 2026VoteReported shareholder vote results. Filing
  5. Jun 15, 2026AnnouncementThe Company issued a press release announcing positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, the Company’s investigational Claudin 6 x CD3 T cell engaging bispecific antibody. Filing
  6. May 18, 2026AgreementContext Therapeutics Inc. entered into a First Amendment to that certain License Agreement, dated September 23, 2024, by and between the Company and BioAtla, Inc. Filing
  7. May 1, 2026AnnouncementAs previously disclosed, on March 11, 2026, the Court of Chancery of the State of Delaware approved a stipulation and proposed consent judgment regarding the stockholder class action complaint filed on February 4, 2026 by the Vladimir Gusinsky Revocable Trust against Context Therapeutics Inc. and… Filing
  8. Apr 2, 2026AnnouncementThe Company issued a press release announcing that the FDA has granted Fast Track designation to CTIM-76, the Company’s investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care… Filing
  9. Mar 23, 2026AnnouncementCorporate Presentation Slides 15 and 32 of Exhibit 99.1 to this Current Report on Form 8-K are hereby incorporated by reference into this Item 8.01. Filing
  10. Mar 13, 2026AnnouncementPursuant to the Stipulated Judgment, the Action was dismissed with prejudice as to plaintiff; however, the Court retains jurisdiction to address any mootness fee application. Filing
  11. Feb 27, 2026AnnouncementA stipulation and proposed consent judgment was filed with the Court of Chancery of the State of Delaware regarding the stockholder class action complaint filed on February 4, 2026 by the Vladimir Gusinsky Revocable Trust against Context Therapeutics Inc. and its directors. Filing
  12. Jan 8, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Context Therapeutics financials

Famous investors that hold CNTX

2 of the 50 well-known investors we track reported holding CNTX in their latest 13F filing. The largest position is Ken Griffin's, worth $299K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026995,887$299K0.0%+5644%
Jim Simons · Renaissance TechnologiesQ3 2026967,475$291K0.0%-7%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Context Therapeutics Inc. (CNTX) stock

Who owns the most CNTX stock?

The largest reported owner of Context Therapeutics Inc. (CNTX) is Nextech Invest Ltd., with 8.1% of the company. In total, 80 funds and institutions reported holding CNTX at the end of Q2 2026, together about 69% of the shares. See the largest owners.

Are CNTX insiders buying or selling?

No CNTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in CNTX?

As of Oct 30, 2026, 4.70M CNTX shares were sold short, 5.1% of the shares outstanding, up 9.9% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 3.7 trading days (days to cover). See the history.

Which famous investors hold CNTX?

2 of the 50 well-known investors we track reported CNTX in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $299K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.